Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Regorafenib voor recidiverend meningeoom graad 2 en 3 (MIRAGE-onderzoek) (MIRAGE)

25 september 2026 bijgewerkt door: Istituto Oncologico Veneto IRCCS

Regorafenib voor recidiverend meningeoom graad 2 en 3. Een multicenter, gerandomiseerde fase II-studie (MIRAGE-studie)

The focus of this study will be to investigate whether Regorafenib demonstrates antitumor activity against recurrent meningiomas.

Small trials and case series suggest clinical relevant activity of several VEGF inhibitors such as sunitinib, bevacizumab and valatinib reporting a 6m-PFS rate of 42-64%. Indeed, VEGF and VEGF receptors (VEGFR) are regularly overexpressed in meningiomas and can correlate with outcome.

Regorafenib inhibits angiogenic receptor tyrosine kinases (RTKs) and is highly selective for VEGFR1/2/3; moreover Regorafenib inhibits PDGFRB, FGFR1 and oncogenic intracellular signalling cascades involving c-RAF/RAF1 and BRAF highly expressed in meningiomas.

Noteworthy, Regorafenib showed antitumor activity in vitro and in vivo in a recent study; indeed, Regorafenib showed significant inhibition of meningioma cell motility and invasion and in vivo, mice with orthotopic meningioma xenografts showed a reduced volume of signal enhancement in MRI following Regorafenib therapy; this translated in a significantly increased overall survival time (p<0.05) for Regorafenib treated mice.

Moreover, Regorafenib showed good efficacy in different cancer types, such as colorectal cancer, GIST, hepatocellular carcinoma and glioblastoma (REGOMA trial) , maintainingmaintaining a good quality of life.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

104

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

  • Italië
      • Bari, Italië
      • Bari, Italië
        • Voltooid
        • Ospedale San Paolo
      • Bologna, Italië
        • Werving
        • Ospedale Bellaria - AUSL Bologna
        • Hoofdonderzoeker:
          • Enrico Franceschi, MD
        • Contact:
      • Florence, Italië
        • Werving
        • Azienda Ospedaliero Universitaria Careggi
        • Contact:
        • Hoofdonderzoeker:
          • Isacco Desideri, MD
      • Genova, Italië
      • Livorno, Italië
      • Milan, Italië
        • Werving
        • Fondazione IRCCS Istituto Neurologico Carlo Besta
        • Contact:
        • Hoofdonderzoeker:
          • Paola Gaviani, MD
      • Milan, Italië
        • Werving
        • IRCCS Ospedale San Raffaele
        • Contact:
        • Hoofdonderzoeker:
          • Nicole Liscia, MD
      • Naples, Italië
        • Werving
        • Ospedale del Mare
        • Hoofdonderzoeker:
          • Bruno Daniele, MD
        • Contact:
      • Padova, Italië, 35128
      • Perugia, Italië
        • Nog niet aan het werven
        • Azienda Ospedaliera di Perugia
        • Contact:
      • Roma, Italië
        • Werving
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
        • Contact:
        • Hoofdonderzoeker:
          • Silvia Chiesa, MD
      • Roma, Italië
        • Nog niet aan het werven
        • Policlinico Umberto I - Università Sapienza Roma
        • Contact:
        • Hoofdonderzoeker:
          • Giuseppe Minniti, MD
      • Roma, Italië
        • Werving
        • IRCCS Istituto Tumori Regina Elena
        • Contact:
        • Hoofdonderzoeker:
          • Veronica Villani, MD
      • Torino, Italië
        • Werving
        • A.O.U. Città della Salute e della Scienza di Torino
        • Contact:
        • Hoofdonderzoeker:
          • Roberta Rudà, MD
    • Forlì-Cesena
      • Meldola, Forlì-Cesena, Italië
        • Werving
        • IRST Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
        • Hoofdonderzoeker:
          • Lorena Gurrieri, MD
        • Contact:
    • Italia/Messina
      • Messina, Italia/Messina, Italië, 98124
    • Italy, Firenze
    • Italy, PN
      • Aviano, Italy, PN, Italië, 33081
        • Nog niet aan het werven
        • Centro di Riferimento Oncologico di Aviano (CRO), IRCCS
        • Contact:
    • Milano
      • Rozzano, Milano, Italië
        • Werving
        • Humanitas Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Matteo Simonelli, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
  • Patients capable of taking oral medication
  • Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
  • Histological diagnosis of meningioma according to the WHO 2021 classification
  • Radiologically documented progression of any existing tumor with an estimated planar growth >25% (bidirectional) in the last 12 months or appearance of new lesions
  • Ineligible for further surgery and/or radiotherapy
  • at least 1 Measurable lesion (minimum 10 x 10mm) on baseline MRI
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 (or KPS ³70)
  • Male or female ≥ 18 years of age
  • Subjects must have life expectancy of at least 6 months
  • Paraffin-embedded tumor tissue available (mandatory)
  • Dosage of dexamethasone or equivalent steroid within 7 days prior the randomization ≤4mg/die
  • Stable or decreasing dosage of steroids for 7 days prior to the randomization.
  • Adequate cardiac function and adequate liver, renal and hematological function
  • Subject must have the following laboratory values at screening within 14 days before starting Regorafenib:
  • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without growth factor support for 7 days (14 days if subject received pegfilgrastim).
  • Hemoglobin (Hgb) ≥10 g/dL
  • Platelet count (plt) ≥100x 109/L
  • Serum potassium concentration within normal range, or correctable with supplements
  • Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) and serum glutamate pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) ≤ 3.0 x Upper Limit of Normal (ULN).
  • Serum total bilirubin ≤ 1.5 x ULN
  • Serum creatinine ≤ 1.5 x ULN or measured glomerular filtration rate (GFR) ≥ 50 mL/min/1.73 m2 using an exogenous filtration marker such as iohexol, inulin, 51Cr EDTA or 1125 iothalamate, or creatinine clearance of ≥ 50 mL/min using Cockroft-Gault equation.
  • Serum albumin > 3.5 g/dL
  • PT (or INR) and APTT within normal range
  • For women who are not postmenopausal (i.e., < 2 years after last menstruation) or surgically sterile (absence of ovaries and/or uterus) and who are sexually active: agreement to use an adequate method of contraception (oral contraceptives, intrauterine contraceptive device, or barrier method of contraception in conjunction with spermicidal jelly) during the Treatment period and for at least 6 months after the last dose of study drug.
  • For male patients who are partners of premenopausal women: agreement to use a barrier method of contraception during the Treatment period and for at least 6 months after the last dose of study drug.
  • Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to participate.
  • 19. Patients with measurable, progressive meningioma who received radiation therapy are potentially eligible but need to show evidence of progression at least 24 weeks from completion of radiation therapy.
  • 20. Possible prior use of bevacizumab in the treatment of radionecrosis (3-24 months after radiosurgery or radiotherapy; 5mg/kg q14w, 4-6 cycles)

Exclusion Criteria:

  • Prior antineoplastic therapy for meningioma
  • Subject incapacitated to understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
  • Are taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's Wort)
  • Are taking strong UGT1A9 inhibitors (e.g. mefenamic acid, diflunisal and niflumic acid)
  • Receiving additional, concurrent, active therapy for Meningioma outside of the trial.
  • Disease outside the brain (ie. spinal cord or bone or metastasis to a distant organ)
  • Candidate for urgent palliative intervention for primary disease (e.g., impending herniation) as judged by the Investigator
  • History of allergy or hypersensitivity to any of the study treatments or any of their excipients.
  • In the presence of therapeutic intent to anticoagulate the patient:,INR or PT and aPTT not within therapeutic limits (according to the medical standard in the institution)
  • Unable or unwilling to undergo brain MRI scans with intravenous (IV) gadolinium
  • History of another malignancy in the previous 3 years, with a disease-free interval of< 3 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible.
  • Serious, non-healing wound, ulcer, bone fracture, or abscess.
  • Any cerebrovascular accident (including transient ischemic attacks) within the last 6 months prior to initiation of study treatment.
  • Have an ongoing infection with severity of Grade 2 or above (CTCAE 5.0)
  • Any hemorrhage or bleeding event that is ≥ Grade 3 based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE), Grade 2 intracranial hemorrhage, or persistent thrombotic/embolic event within 4 weeks prior to the start of study medication.
  • Uncontrolled or severe cardiac disease (e.g., history of unstable angina, myocardial infarction, coronary stenting, or bypass surgery within the last 6 months prior to initiation of study treatment), symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation), requirement for inotropic support or use of devices for cardiac conditions (e.g.,pacemakers/defibrillators), or hypertension (participants with systolic blood pressure[BP] of > 160 mmHg or diastolic BP of > 100 mmHg despite optimal medical management are to be excluded).
  • History of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, or symptomatic pleural effusion.
  • Active, known, or suspected auto-immune disease, including systemic lupus erythematosus, Hashimotos thyroiditis, scleroderma, polyarteritis nodosa, or auto-immune hepatitis.
  • Known history of hepatitis B, human immunodeficiency virus (HIV), or active hepatitis C infection requiring treatment with antiviral therapy. Note: HIV testing is not required in the absence of clinical suspicion.
  • History of bleeding diathesis (irrespective of severity).
  • Uncontrolled intercurrent illness including (e.g., symptomatic ascites), but not limited to ongoing or active infection.
  • Persistent ≥ Grade 3 Lipase (> 2.0 - 5.0 x upper limit of normal [ULN] with signs or symptoms; > 5.0 x ULN and asymptomatic).
  • Persistent proteinuria > 3.5 g/24 hours measured by urine protein creatinine ratio from a random urine sample (≥ Grade 3, CTCAE 5.0)
  • Have any malabsorbition condition
  • Any condition that could make the subject noncompliant with the study procedures and/or study requirements, as judged by the Investigator (for example: cognitive impairment, psychiatric illness, etc).

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Arm A (interventional arm)

REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
Geneesmiddel: Regorafenib 40 MG Oral Tablet

REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
Actieve vergelijker: Arm B (control arm)

Local Standard of Care until disease progression or unacceptable toxicity
Geneesmiddel: Local Standard of Care

In this setting there are not drugs with indication. Every site will treat patients as per their experience.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Progression free survival (PFS)
Tijdsspanne: Up to 54 months

The progression free survival (PFS) will be determined as the time from the date of enrolment to the date of disease progression determined using RANO criteria or to the date of death, whichever occurs first.
Up to 54 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Overall survival (OS)
Tijdsspanne: Up to 42 months

The overall survival (OS) will be determined as the time from the date of enrolment to the date of death from any cause.
Up to 42 months
Objective response rate (ORR)
Tijdsspanne: Up to 42 months

The objective response rate (ORR) will be defined as the percentage of patients with complete response (CR) and partial response (PR) determined using modified Macdonald criteria.
Up to 42 months
Patient Reported Outcomes (PROs)
Tijdsspanne: Up to 42 months

Quality of life will be assessed by EORTC QLQ-C30 questionnaire.
Up to 42 months
Patient Reported Outcomes (PROs)
Tijdsspanne: Up to 42 months

Quality of life will be assessed by the QLQBN20 questionnaire.
Up to 42 months
Toxicity during treatment
Tijdsspanne: Up to 42 months

Toxicity during the treatment will be recorded and graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v.5.
Up to 42 months
Disease control rate (DCR)
Tijdsspanne: Up to 42 months

The disease control rate (DCR) will be defined as the percentage of patients with complete response (CR), partial response (PR) and stable disease (SD) determined using modified Macdonald criteria.
Up to 42 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Istituto Oncologico Veneto IRCCS

Medewerkers

Bayer

Onderzoekers

  • Hoofdonderzoeker: Giuseppe Lombardi, MD, Istituto Oncologico Veneto IOV IRCCS

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

23 september 2024

Primaire voltooiing (Geschat)

1 december 2028

Studie voltooiing (Geschat)

1 maart 2029

Studieregistratiedata

Eerst ingediend

7 februari 2024

Eerst ingediend dat voldeed aan de QC-criteria

16 februari 2024

Eerst geplaatst (Werkelijk)

23 februari 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

30 september 2026

Laatste update ingediend die voldeed aan QC-criteria

25 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • IOV-BT-1-2023 MIRAGE

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren